Description:

ODM derived from http://clinicaltrials.gov/show/NCT00749723

Link:

http://clinicaltrials.gov/show/NCT00749723

Keywords:
Versions (3) ▾
  1. 12/6/13
  2. 4/16/14
  3. 9/20/21
Uploaded on:

September 20, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00003778 NCT00749723 Recurrent Brain Tumors

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age 3 Months to 30 Years
Histologically confirmed Medulloblastoma, cerebral PNET or Ependymoma
Refractory or relapsed disease
Measurable disease by MRI or detection of tumor cells in cerebrospinal fluid
Performance status ECOG >= 3 or Karnofsky Status >= 40%
Life expectancy >= 8 weeks
Absolute leukocyte count >= 2.0 x 10^9 /l
Hemoglobin, Hemoglobin Measurement
Platelet count - finding
Creatinine no greater than 1.5 times UNL
No overt renal disease
Bilirubin < 2.5 times UNL
AST and ALT < 5 times UNL
No overt hepatic disease
No overt pulmonary disease
No overt cardiovascular disease
Not pregnant or nursing
Negative Pregnancy Test
Fertile patients must use effective contraception
No uncontrolled infection prior concurrent therapy
> 2 weeks since prior systemic chemotherapy
> 4 weeks since prior radiotherapy
No other concurrent anticancer or experimental drugs
Examination of lumbar CSF
Cranial and spinal MRI within 14 days prior to start of treatment

Similar models